Phase 1 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 54 years old who are generally healthy, male or female, and able to give written consent before the trial begins.
• People with a body mass index (BMI) between 18 and 32, where male participants weigh at least 50 kg and female participants weigh at least 40 kg.
• People who agree not to try to conceive a child, to use reliable contraception, and not to donate eggs or sperm from 30 days before receiving the study drug until 120 days after. For women who could become pregnant, hormonal contraception should have been started at least one month before the screening visit.

Who may not be able to join:

• People with a known history of significant drug allergies, allergic conditions such as asthma, hives, or eczema, or known allergies to biologic medicines or their ingredients. (Childhood asthma that has fully resolved may not be a barrier — confirm with trial site.)
• People with any significant health condition affecting the nervous system, heart, digestive system, lungs, kidneys, blood, or hormonal/metabolic systems that could affect safety during the trial.
• People who have taken prescription medications within 14 days or five half-lives before the study drug is given (whichever period is longer), unless the trial investigators and sponsor determine those medications will not interfere.
• People who have taken over-the-counter medicines or herbal remedies within 7 days or five half-lives before the study drug is given (whichever is longer), unless determined not to interfere by the trial team.
• People with a history of drug misuse within the 12 months before dosing.
• People who cannot tolerate injections, or who have a history of fainting at the sight of needles or blood.
• People who have taken part in another clinical trial (for a drug or medical device) within 30 days before dosing, or within seven times the known elimination half-life of that trial's product, whichever is longer.
• People who have donated blood or had a significant blood loss (more than 300 mL) within 30 days before dosing, or who plan to donate blood during the study.
• People who have received a live vaccine (other than influenza) within 60 days before dosing.
• People whose liver enzyme levels (AST or ALT) are 1.5 times or more above the normal upper limit, or whose total bilirubin is above the normal upper limit, at the screening visit or two days before dosing (with a possible exception for a condition called Gilbert's disease — confirm with trial site).
• People whose kidney function, as measured by estimated creatinine clearance, falls below 80 mL/min at screening or two days before dosing.
• People who test positive for syphilis, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, or HIV antibody at screening.
• People whose urine drug screening test is positive at screening or two days before dosing.
• People whose brain MRI shows small bleeds, a condition called superficial siderosis, previous evidence of microhemorrhage, or any other significant brain abnormality.
• People who need to or plan to do intense physical exercise or vigorous activity during the study period.
• People whom the trial investigators consider unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.